Bromide

Bromide

SCHEMBL4326424

Br.CCCC1CN(CC(=O)c2cc(N3CCC(OCC(=O)O)C3)c(O)c(C(C)(C)C)c2)C(=N)C1c1ccccc1

nearest known ligand 0.36

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
ACHE known ✓ P22303 2/20 0.34
F2R P25116 10/20 0.36
LIPG Q9Y5X9 4/20 0.34
LIPC P11150 2/20 0.34
MAOB P27338 2/20 0.34
BCHE P06276 2/20 0.34
MAOA P21397 2/20 0.34
LPL P06858 1/20 0.32
TTR P02766 1/20 0.32
PTGIR P43119 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13751184 0.99 F2R (0.37) F2RLIPGLIPCMAOBBCHE
Bromide SCHEMBL4319735 0.94 LIPG (0.35) F2RLIPGLIPCMAOBBCHE
SCHEMBL13751188 0.93 LIPG (0.36) F2RLIPGLIPCMAOBBCHE
SCHEMBL13758405 0.89 LIPG (0.33) F2RLIPGLIPCMAOBBCHE
SCHEMBL13751025 0.83 F2R (0.48) F2RMAOBBCHEMAOAACHE
SCHEMBL4345531 0.83 F2R (0.48) F2RMAOBBCHEMAOAACHE
Hydrochloric Acid SCHEMBL4325954 0.83 F2R (0.48) F2RMAOBBCHEMAOAACHE
SCHEMBL13758365 0.83 LIPG (0.34) F2RLIPGLIPCMAOBBCHE
Bromide SCHEMBL4325949 0.81 F2R (0.39) F2RMAOBBCHEMAOAACHE
SCHEMBL13751180 0.81 F2R (0.39) F2RMAOBBCHEMAOAACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090215795-A1 CYCLIC AMIDINE DERIVATIVES EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-08-27 US disclosed
EP-1386912-B1 CYCLIC AMIDINE DERIVATIVE EISAI R&D MAN CO LTD (JP) 2009-03-18 EP disclosed
US-7476688-B2 Cyclic amidine derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-01-13 US disclosed
US-20040254376-A1 Cyclic amidine derivative EISAI R&D MANAGEMENT CO., LTD. (JP) 2004-12-16 US disclosed
EP-1386912-A1 CYCLIC AMIDINE DERIVATIVE Eisai Co., Ltd. (JP) 2004-02-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254376-A1 Cyclic amidine derivative ARGLU1, ARG1, PRMT1 ACHE 3494/4885F2R 2745/4885LIPG 4753/4885
US-20090215795-A1 CYCLIC AMIDINE DERIVATIVES H1-10, H1-3, H1-4 ACHE 2173/4885F2R 1447/4885LIPG 4816/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.